Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$41.99 - $62.38 $5.32 Million - $7.9 Million
-126,585 Reduced 52.19%
115,976 $6.81 Million
Q3 2023

Nov 09, 2023

BUY
$27.8 - $45.35 $195,489 - $318,901
7,032 Added 2.99%
242,561 $10.6 Million
Q2 2023

Aug 14, 2023

SELL
$36.13 - $49.49 $120,168 - $164,603
-3,326 Reduced 1.39%
235,529 $8.51 Million
Q1 2023

May 15, 2023

BUY
$36.54 - $54.26 $421,452 - $625,834
11,534 Added 5.07%
238,855 $8.88 Million
Q4 2022

Feb 13, 2023

BUY
$41.27 - $98.62 $1.02 Million - $2.43 Million
24,688 Added 12.18%
227,321 $10.3 Million
Q3 2022

Nov 14, 2022

SELL
$59.5 - $86.7 $1.79 Million - $2.61 Million
-30,119 Reduced 12.94%
202,633 $14.2 Million
Q2 2022

Aug 11, 2022

BUY
$39.16 - $88.71 $369,239 - $836,446
9,429 Added 4.22%
232,752 $15.6 Million
Q1 2022

May 13, 2022

BUY
$75.82 - $150.97 $301,991 - $601,313
3,983 Added 1.82%
223,323 $18.4 Million
Q4 2021

Feb 11, 2022

SELL
$132.01 - $190.29 $44.9 Million - $64.8 Million
-340,348 Reduced 60.81%
219,340 $32.2 Million
Q3 2021

Nov 04, 2021

SELL
$132.13 - $177.45 $177,582 - $238,492
-1,344 Reduced 0.24%
559,688 $99 Million
Q2 2021

Aug 11, 2021

BUY
$144.0 - $179.73 $48.1 Million - $60 Million
333,765 Added 146.86%
561,032 $90.6 Million
Q1 2021

May 13, 2021

SELL
$158.92 - $221.61 $4.99 Million - $6.95 Million
-31,381 Reduced 12.13%
227,267 $38.9 Million
Q4 2020

Feb 16, 2021

BUY
$162.05 - $240.27 $22 Million - $32.6 Million
135,642 Added 110.27%
258,648 $56.8 Million
Q3 2020

Nov 12, 2020

SELL
$113.26 - $167.27 $4.54 Million - $6.71 Million
-40,112 Reduced 24.59%
123,006 $20.4 Million
Q2 2020

Aug 13, 2020

SELL
$72.01 - $120.39 $4.87 Million - $8.13 Million
-67,569 Reduced 29.29%
163,118 $18.6 Million
Q1 2020

May 14, 2020

SELL
$69.78 - $116.21 $1.02 Million - $1.71 Million
-14,676 Reduced 5.98%
230,687 $17.7 Million
Q4 2019

Feb 14, 2020

BUY
$70.76 - $128.86 $11.4 Million - $20.8 Million
161,127 Added 191.28%
245,363 $31.6 Million
Q3 2019

Nov 14, 2019

SELL
$77.91 - $109.6 $18.5 Million - $26.1 Million
-237,971 Reduced 73.86%
84,236 $6.56 Million
Q2 2019

Aug 14, 2019

BUY
$59.49 - $104.71 $14.9 Million - $26.2 Million
250,442 Added 348.98%
322,207 $33.2 Million
Q1 2019

May 15, 2019

SELL
$43.65 - $78.95 $755,494 - $1.37 Million
-17,308 Reduced 19.43%
71,765 $5.26 Million
Q4 2018

Feb 14, 2019

SELL
$32.0 - $47.43 $4.98 Million - $7.39 Million
-155,774 Reduced 63.62%
89,073 $3.78 Million
Q3 2018

Dec 21, 2021

BUY
$47.1 - $62.7 $3.5 Million - $4.66 Million
74,388 Added 43.64%
244,847 $11.5 Million
Q3 2018

Nov 14, 2018

BUY
$47.1 - $62.7 $3.07 Million - $4.08 Million
65,133 Added 61.84%
170,459 $8.03 Million
Q2 2018

Apr 21, 2020

BUY
$26.05 - $52.4 $172,763 - $347,516
6,632 Added 6.72%
105,326 $5.19 Million
Q2 2018

Aug 14, 2018

SELL
$26.05 - $52.4 $1.07 Million - $2.15 Million
-41,076 Reduced 29.39%
98,694 $4.86 Million
Q1 2018

Oct 18, 2019

BUY
$17.2 - $34.95 $600,847 - $1.22 Million
34,933 Added 33.32%
139,770 $4.29 Million
Q1 2018

May 15, 2018

BUY
$17.2 - $34.95 $1.77 Million - $3.61 Million
103,180 Added 6226.92%
104,837 $3.22 Million
Q4 2017

Feb 14, 2018

SELL
$12.65 - $19.0 $188,333 - $282,872
-14,888 Reduced 89.98%
1,657 $30,000
Q3 2017

Nov 14, 2017

BUY
$4.7 - $11.7 $77,761 - $193,576
16,545
16,545 $193,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.